Oncology

Adding temozolomide (Temodar) to chemoradiation reduced the risk of death by 33% in elderly glioblastoma patients.

Increased unemployment shows a negative impact on worldwide cancer mortality.

Aggressive treatment approach shows promise in children with high risk brain cancer.

Choosing Wisely recommendations have not substantially changed the care received by patients in the last 30 days of life.

Access to new cancer medications varies greatly by country.

Top news of the day from across the health care landscape.

Immunotherapy combination increased T cell activity in the blood and the patient went into remission.

Risk of developing breast cancer in women with a BRCA1 mutation may be reduced.

Women diagnosed with breast cancer who carry a BRCA mutation have up to a 50% lifetime risk of developing a second breast cancer.

Patients treated with chemotherapy and IMAB362 had a median overall survival of 16.7 months.

Patients treated with atezolizumab had a longer median overall survival than patients treated with carboplatin-based regimens.

Male mice that ate 10.5% of their calories in walnuts had 2.3 times less tumors.

Postmenopausal women with early breast cancer showed a reduction in disease recurrence after 10 years of aromatase inhibitor therapy with letrozole.

Targeted treatment shows strongest efficacy in HER2 abnormalities.

Ultrasound and chemotherapy in conjunction with microbubbles enhances pancreatic cancer treatment.

Biosimilar trastuzumab antibody (MYL-1401O) comparable in efficacy and safety to targeted cancer drug in women with HER2-positive advanced breast cancer.

Patients receiving intraperitoneal and intravenous chemotherapy had progression-free survival of 59.3 months.

Capecitabine chemotherapy in combination with gemcitabine show median overall survival rate of 28 months.

Anaplastic glioma patients administered temozolomide after radiation, with or without concurrent temozolomide, saw a slower progression of the disease.

Precision medicine found to be associated with increased tumor reduction and progression-free survival.

The amount public health insurance programs reimburse for new cancer drugs varies in different countries.

Access to new cancer medications varies greatly by country.

Overall 3-year survival in patients with advanced melanoma taking pembrolizumab was 40%.

Thiazole benzensulfonamides (TZB) show useful anticancer properties.

Alcohol found to affect biologic mechanisms that raise the risk of cancer.

Hsp90 inhibitors target and inactivate a mechanism that cancer cells use to evade standard treatments.

Access to oral chemotherapies is filled with challenges for providers and patients that can be significant, resulting in delayed therapy.

Physicians are challenged with differentiating among a wide array of treatment options, with varying regimens and indications, and then monitoring patients according to the specific guidelines for each therapy.